Skip to main content
OpenTrials

Clinical trial condition

Medullary Thyroid Cancer

Explore clinical trials studying Medullary Thyroid Cancer. Study availability and eligibility vary by location and protocol.

24 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Medullary Thyroid Cancer trial results

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

NCT04211337

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • City of Hope National Medical Center Duarte, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 100) Los Angeles, California, United States
  • University of California Davis (UC Davis) Comprehensive Cancer Center Sacramento, California, United States
View all 143 locations
View Trial Details
Active, not recruiting

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

NCT03899792

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Breast Diseases, +52 more
Locations
  • Childrens Hospital of Los Angeles Los Angeles, California, United States
  • The Children's Hospital for Cancer and Blood Disorders Aurora, Colorado, United States
  • Nemours Children's Health Orlando, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 26 locations
View Trial Details
Completed

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

NCT01298323

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +15 more
Locations
  • Investigational Site Number : 301 St Leonards, New South Wales, Australia
  • Investigational Site Number 301 St Leonards, Australia
  • Investigational Site Number 401 Vienna, Austria
  • Investigational Site Number : 401 Vienna, Austria
View all 66 locations
View Trial Details
Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT03037385

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Diseases, +55 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • UC Irvine Medical Center Orange, California, United States
  • University of Colorado Anschutz Medical Campus Aurora, Colorado, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
View all 71 locations
View Trial Details
Completed

Predictive Factors for Medullary Thyroid Cancer Aggressiveness

NCT06292988

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more
Locations
  • Oregon Health & Science University, Oregon Oregon City, Oregon, United States
  • Department of Surgery, Saint John of God Hospital, Salzburg, Austria Salzburg, Austria
  • Saint Luc, University Clouvain, Belgium Brussels, Belgium
  • Head and Neck Surgery Department, Hospital Ana Nery, Santa Cruz do Sul, Brazil Santa Cruz do Sul, Brazil
View all 46 locations
View Trial Details

Related conditions